Schönfeld Kurt, Zuber Chantal, Pinkas Jan, Häder Thomas, Bernöster Katrin, Uherek Christoph
Biotest AG, Landsteinerstraße 5, 63303, Dreieich, Germany.
ImmunoGen Inc., 830 Winter Street, Waltham, 02451-1477, MA, USA.
J Hematol Oncol. 2017 Jan 11;10(1):13. doi: 10.1186/s13045-016-0380-0.
Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve host survival. Here, we show that in most cell lines tested, indatuximab ravtansine acts additively or even synergistically with clinically approved therapies for treatment of multiple myeloma. In addition, in vivo mouse xenograft models confirmed the activity of indatuximab ravtansine in combination with lenalidamide and lenalidomide/dexamethasone. Indatuximab ravtansine may therefore be a suitable combination partner for multiple myeloma, and a clinical study is ongoing.
因达妥昔单抗拉伐他辛是一种单克隆抗体连接的细胞毒性药物，可特异性靶向表达CD138的细胞。单药治疗已显示出可在体内显著抑制多发性骨髓瘤肿瘤生长并提高宿主存活率。在此，我们表明，在大多数测试的细胞系中，因达妥昔单抗拉伐他辛与治疗多发性骨髓瘤的临床批准疗法具有相加甚至协同作用。此外，体内小鼠异种移植模型证实了因达妥昔单抗拉伐他辛与来那度胺以及来那度胺/地塞米松联合使用的活性。因此，因达妥昔单抗拉伐他辛可能是多发性骨髓瘤的合适联合用药伙伴，一项临床研究正在进行中。
